Research Idea
Research content for general circulation. Not individualized advice.Ā Methodology & Disclosures
Positive catalyst stack with FDA approval of romidepsin injection solution including 180 days of exclusivity, solid Q1 2026 revenue/adjusted EBITDA, reaffirmed higher full-year guidance, and a 14% 21-day stock uptrend with recent breakout strength.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ā¢ Higher lows ā¢ Overhead resistance ā¢ Trend cooling Support Level: $17.00-$17.20 Resistance Level: $18.00-$18.10 AMRX has maintained a constructive short-term uptrend over the last month, but after rebounding from $16.69 it is now consolidating just below $18.10 with support near $17.00-$17.20 and cooling near-term momentum.
Sentiment & News
Key News Insights: ā¢ Pipeline progress ā¢ Generics expansion ā¢ Legal scrutiny AMRX showed steady product/portfolio progress with positive European and FDA updates, but the late-July shareholder investigation adds a legal overhang.
AI Summary
AMRX has shifted from a speculative turnaround to an execution-driven rerating story, with real earnings, raised guidance, and new approvals supporting upside, but after the sharp run-up and higher valuation the stock now needs continued commercial conversion and regulatory follow-through to avoid a disappointment-driven pullback.
Description
Amneal Pharmaceuticals is a manufacturer and distributor of generic and specialty medicines, operating three reporting segments: Generics, Specialty and AvKARE. Its Generics business produces a broad range of dosage forms while the Specialty unit markets branded therapies across several therapeutic areas; AvKARE supplies pharmaceuticals, medical and surgical products, and packaging services primarily to government and institutional customers. The company sells through wholesalers, hospitals and pharmacies, and maintains operations in the United States, India, Ireland and other international markets; it is headquartered in Bridgewater, New Jersey and was founded in 2002.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 9 | Jun 16 | AMRX | Amneal Pharmaceuticals, Inc. | Positive catalyst stack with FDA approval of romidepsin injection solution including 180 days of exclusivity, solid Q1 2026 revenue/adjusted EBITDA, reaffirmed higher full-year guidance, and a 14% 21-day stock uptrend with recent breakout strength. | Closed | +10.6% |